<DOC>
	<DOCNO>NCT00573508</DOCNO>
	<brief_summary>Evaluate effect VESIcare® symptom bother subject OAB</brief_summary>
	<brief_title>Study VESIcare® In Overactive Bladder ( OAB ) Subjects Evaluate Symptom Bother Health Related Quality Life</brief_title>
	<detailed_description>Phase 4 , multi-center , randomize , double-blind , placebo-controlled , parallel group study . All subject meet baseline criterion randomize 1:1 ratio VESIcare® ( solifenacin succinate ) placebo group . The study duration consist screen period include minimum 14 day treatment free wash-out period . Subjects meet baseline criterion 12 week treatment period . Maximum total study duration 15 week : 2 3 week screen / washout period ; 12 week double-blind treatment . Primary efficacy base OAB-q symptom bother score .</detailed_description>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<criteria>Ambulatory male female subject ≥ 18 year age able use toilet without difficulty History OAB symptom ≥ 3 month An average ≥ 8 micturition per 24 hour ≥ 1 urgency episode ( without incontinence ) per 24 hour document 3day micturition diary Subjects bother symptom reflect PPBC ≥3 Evidence chronic urologic inflammation interstitial cystitis bladder stone ; uncontrolled narrow angle glaucoma ; urinary gastric retention Recurrent urinary tract infection ( UTI ) &gt; 3 episode within last 3 month evidence urinary tract infection Baseline Visit ( Visit 2 ) Significant stress incontinence mixed stress/urge incontinence stress predominant factor determine investigator History renal hepatic impairment ( 2 x Upper Limit Normal ( ULN ) value parameter consider clinically significant investigator History diagnose gastrointestinal obstruction disease Subject know diagnosis history carcinoma ( include prostate cancer ) except non metastatic basal squamous cell carcinoma skin successfully treat previous pelvis radiation within past five year Known suspected hypersensitivity solifenacin succinate , component , anticholinergic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Overactive Bladder</keyword>
</DOC>